Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study.
Pincikova T, Nilsson K, Moen IE, Karpati F, Fluge G, Hollsing A, Knudsen PK, Lindblad A, Mared L, Pressler T, Hjelte L; Scandinavian Cystic Fibrosis Study Consortium. Pincikova T, et al. Among authors: hjelte l. Eur J Clin Nutr. 2011 Jan;65(1):102-9. doi: 10.1038/ejcn.2010.194. Epub 2010 Sep 22. Eur J Clin Nutr. 2011. PMID: 20859300
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Wainwright CE, et al. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981758 Free PMC article. Clinical Trial.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group. Ratjen F, et al. Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Lancet Respir Med. 2017. PMID: 28606620 Free article. Clinical Trial.
Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.
Al Shakirchi M, Sorjonen K, Hjelte L, Klingspor L, Bergman P, Ericson P, Svedberg M, Lindberg U, Hansen C, Monestrol I. Al Shakirchi M, et al. Among authors: hjelte l. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241254090. doi: 10.1177/17534666241254090. Ther Adv Respir Dis. 2024. PMID: 38780228 Free PMC article.
Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination.
Stone VM, Utorova R, Butrym M, Sioofy-Khojine AB, Hankaniemi MM, Ringqvist EE, Blanter M, Parajuli A, Pincikova T, Fischler B, Karpati F, Hytönen VP, Hyöty H, Hjelte L, Flodström-Tullberg M. Stone VM, et al. Among authors: hjelte l. iScience. 2022 Sep 5;25(10):105070. doi: 10.1016/j.isci.2022.105070. eCollection 2022 Oct 21. iScience. 2022. PMID: 36157581 Free PMC article.
MAIT cell counts are associated with the risk of hospitalization in COPD.
Pincikova T, Parrot T, Hjelte L, Högman M, Lisspers K, Ställberg B, Janson C, Malinovschi A, Sandberg JK. Pincikova T, et al. Among authors: hjelte l. Respir Res. 2022 May 18;23(1):127. doi: 10.1186/s12931-022-02045-2. Respir Res. 2022. PMID: 35585629 Free PMC article.
93 results